Compare State Street SPDR S&P Biotech ETF (XBI) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Materials Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $160, while Materials Select Sector SPDR Fund trades at $51.45. Which is the better fit depends on your goals.
| XBI | XLB | |
|---|---|---|
Sector | Broad Market / Factor | — |
52-Week High | $169.55 | $53.67 |
52-Week Low | $93.43 | $42.23 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
XLB trades at $51.95, down 0.93% on the day, with technical indicators showing a bullish overall signal driven by moving averages. The ETF offers broad exposure to the materials sector, which is benefiting from infrastructure spending and AI-related demand. Recent news highlights the sector's potential for earnings growth and defensive characteristics in the current market environment.
The materials sector appears well-positioned for continued growth with strong Q2 earnings momentum and AI infrastructure tailwinds. However, investors face risks from cyclical sector exposure and potential geopolitical supply chain disruptions. Current technical strength suggests near-term upside potential, though valuation metrics remain unavailable for detailed fundamental assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
